Balyasny Asset Management
BIVV

Balyasny Asset Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Balyasny Asset Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,266
Closed -$358K – 2503
2017
Q3 		$358K Buy
6,266
+1,683
+37% +$98.6K ﹤0.01% 1460
2017
Q2 		$276K Sell
4,583
-283,537
-98% -$16.1M ﹤0.01% 1322
2017
Q1 		$15.7M Buy
+288,120
New +$14.2M 0.07% 350

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Balyasny Asset Management's BIVV Position: Q4 2017 in Review

Balyasny Asset Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 6,266 shares — an estimated $358K sold.

Balyasny Asset Management first reported a position in BIVV in Q1 2017 and held it in 3 quarters. The position peaked at $15.7M in Q1 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Balyasny Asset Management reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Balyasny Asset Management sold 6,266 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $358K.
  • Balyasny Asset Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Balyasny Asset Management's Bioverativ Inc. Common Stock position peaked at $15.7M in Q1 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Balyasny Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.